{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:48:39Z","timestamp":1772160519422,"version":"3.50.1"},"reference-count":23,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,8,15]],"date-time":"2007-08-15T00:00:00Z","timestamp":1187136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2007,10]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVES<\/jats:title>\n                    <jats:p>To evaluate the efficacy of tamsulosin oral\u2010controlled absorption system (OCAS) vs placebo in overactive bladder (OAB), to evaluate the safety and tolerability of once\u2010daily dosing with tamsulosin OCAS, and to compare the efficacy and safety with tolterodine extended\u2010release (ER).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PATIENTS AND METHODS<\/jats:title>\n                    <jats:p>A parallel\u2010group, multicentre, multinational study was conducted with a single\u2010blind placebo run\u2010in period of 2\u2003weeks, followed by a randomized, double\u2010blind, double\u2010dummy active and placebo\u2010controlled treatment period of 6\u2003weeks; women (aged 18\u201370\u2003years) with symptoms of OAB for \u2265\u200a3\u2003months were recruited. Women were randomized to receive one of four doses of tamsulosin OCAS (0.25, 0.5, 1.0 or 1.5\u2003mg), 4\u2003mg of tolterodine ER, or placebo once daily for 6\u2003weeks. The primary efficacy variable was the change in the mean number of voids\/24\u2003h. Secondary efficacy variables included change from baseline in; mean volume voided per void, mean number of incontinence episodes\/24\u2003h, mean number of urgency episodes\/24\u2003h and in quality of life (QoL), as assessed using the Kings Health Questionnaire (KHQ).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Overall, 364 women were randomized; the primary efficacy analysis showed that the difference from placebo in the mean number of voids\/24\u2003h was not statistically significant for tamsulosin OCAS 1.5\u2003mg (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.189). There was no statistically significant difference for tolterodine ER 4\u2003mg vs placebo in the mean number of voids\/24\u2003h (\n                      <jats:italic>P<\/jats:italic>\n                      \u2003=\u20030.353). Similarly, for the secondary outcome variables there was no statistically significant difference between tamsulosin and placebo. Although women taking tolterodine ER 4\u2003mg had a consistently greater increase in mean voided volume\/void and consistent decreases in incontinence episodes\/24\u2003h, urgency episodes\/24\u2003h and episodes of nocturia\/24\u2003h, this was not statistically significant. There was no significant improvement in QoL scores across the treatment groups. Tamsulosin OCAS was well tolerated and the proportion of women discontinuing because of adverse events was low (4.7%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Tamsulosin is not effective for treating OAB in women and the evidence from this study does not support its use on an empirical basis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/j.1464-410x.2007.07162.x","type":"journal-article","created":{"date-parts":[[2007,8,17]],"date-time":"2007-08-17T00:25:00Z","timestamp":1187310300000},"page":"840-845","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["A randomized double\u2010blind placebo\u2010controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome"],"prefix":"10.1111","volume":"100","author":[{"given":"Dudley","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Cardozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerben","family":"Terpstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Bolodeoku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Tamsulosin Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,15]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"e_1_2_7_3_2","first-page":"S66","article-title":"Prevalence of overactive bladder in women: results from the NOBLE program","volume":"12","author":"Stewart WF","year":"2001","journal-title":"Int Urogynaecol J"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(97)00595-5"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-0528.1997.tb12054.x"},{"key":"e_1_2_7_7_2","first-page":"S121","article-title":"Persistence with overactive bladder pharmacotherapy in a Medicaid population","volume":"11","author":"Shaya FT","year":"2005","journal-title":"Am J Manag Care"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2005.00617.x"},{"key":"e_1_2_7_9_2","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0022-5347(01)62836-2","article-title":"\u03b11 Adrenergic receptor subtypes in human detrusor","volume":"160","author":"Malloy BJ","year":"1998","journal-title":"J Urol"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2000.00098.x"},{"issue":"1","key":"e_1_2_7_11_2","first-page":"47","article-title":"\u03b11\u2010Adrenergic blocking drugs in bladder outflow obstruction: What potential has \u03b11\u2010adrenoceptor selectivity?","volume":"76","author":"Chapple CR","year":"1995","journal-title":"Br J Urol"},{"issue":"2","key":"e_1_2_7_12_2","first-page":"1","article-title":"Issues of uroselectivity in male and female LUTS","volume":"86","author":"Blaivis JG","year":"2000","journal-title":"BJU Int"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.2000.00062.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-001-0237-0"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.00983.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(75)90012-6"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1979.tb02867.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1993.tb16188.x"},{"key":"e_1_2_7_19_2","first-page":"308","article-title":"Urinary incontinence caused by prazosin","volume":"33","author":"Rachagan SP","year":"1992","journal-title":"Singapore Med J"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0029-7844(97)00497-3"},{"key":"e_1_2_7_21_2","first-page":"558","article-title":"Prazosin\u2010induced stress incontinence","volume":"75","author":"Wall LL","year":"1990","journal-title":"Obstet Gynaecol"},{"key":"e_1_2_7_22_2","first-page":"117","article-title":"Prazosin: a neglected cause of genuine stress incontinence","volume":"79","author":"Dwyer PL","year":"1992","journal-title":"Obstet Gynaecol"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(00)01113-4"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-002-1009-0"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1464-410X.2007.07162.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1464-410X.2007.07162.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:52:37Z","timestamp":1761760357000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/j.1464-410X.2007.07162.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,15]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,10]]}},"alternative-id":["10.1111\/j.1464-410X.2007.07162.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1464-410x.2007.07162.x","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.1090972.544337","asserted-by":"object"}]},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,15]]},"assertion":[{"value":"2007-08-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}